Following hundreds of poison control center calls and a number of hospitalizations, the FDA published a consumer update and warning to the public on the potential health risks associated with consuming delta-8 THC products.
The FDA issued warning letters to two companies this month, alleging FD&C Act violations stemming from marketing new drugs without approval. Companies marketing CBD products should be careful not to market OTC drugs containing CBD.
The post FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products appeared first on Cannabis Industry Journal.
Focusing on quality in the cannabis industry doesn’t just mean quality in cannabis, it should also speak to the quality of your supplies, equipment and materials. In this case study, an FDA-compliant food grade glove was the cause of a cannabis product recall.
In a press release published last week, the two companies announced they have entered an agreement for Jazz to acquire GW Pharma, the producer of the only FDA-approved CBD medication Epidiolex, for a total of $7.2 billion.